Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Key Events in Neurodevices This Year | Main | Getting Government Grants in Neurotechnology »

October 23, 2005

Northstar Neuroscience - Launching a Neurotech Start up

Email This Entry

Posted by Zack Lynch

Northstar Neuroscience CEO Alan Levy began the conference with a talk on how to launch a neurotech start-up. Key points:

1) Neurotech investors are looking for a large unmet need, strong IP portfolio, good science, experienced management team and attractive margins.

2) Northstar has developed a platform technology based on stimulation of cortex initially focused on stroke but in clinical trials for other indications. Why cortical stimulation? Unlike Deep Brain Stimulation (DBS) which requires extensive brain surgery, cortical stimulation sits on the surface of the brain (the dura) which does not require going deep into the brain, neurosurgeons consider implantation minimally invasive taking less than an hour.

3) Stroke: there are over 1 million a year in the U.S., with over 5 million Americans stroke survivors severely limited in their ability to live normal lives.

4) Cortical stimulation can bring back movement to pre-stroke abilities in rats and monkeys, histological analysis showed that dendrites grow back showing that stimulation accompanies neuroplasticty.

5) Northstar stroke trials: Patients with more than 4 months post stroke. Ranged from 4 months to 8 years. Looking for 10% improvement and what Northstar saw was 20-30% improvement in functions. Improvements are sustained over many months allowing people to go back to work, caring for children etc...Currently in pivotal trial.

6) Second application: Aphasia, 20% of stroke survivors suffer from speech disability. Average Sales Price of 15-20K,

7) IP: More than 40 primary filings in cortical stimulation, generate over 100 patents. Mayfield, Domain, Canaan, Boston Scientific, J&J are investors.

8) We are in healthcare to make a difference. The money will come if you provide real value.

Comments (1) + TrackBacks (0) | Category: Neurodevices


COMMENTS

1. Son of Stroke Patient on March 28, 2006 2:02 PM writes...

Let me see, a $2 strap or a $20,000 invasive procedure?

Forbes Magazine
Restraint Therapy Improves Function for Stroke Patients
03.02.06, 12:00 AM ET

THURSDAY, March 2 (HealthDay News) -- A stroke-rehabilitation treatment that restrains a healthy arm can restore function to the damaged arm years after the brain attack, a new study shows.

The finding upsets the conventional belief that only immediate treatment can be effective for people who have strokes, said Gitendra Uswatte, an assistant professor of psychology and a member of the University of Alabama at Birmingham team reporting the findings.

The study was led by Edward Taub, a professor of psychology at the university, who pioneered the treatment that forces patients to use their stroke-weakened arm.

"The traditional wisdom has been that patients more than a year after a stroke have no capacity to regain function," Uswatte said. "This study challenges that."

The findings appear in the March 3 issue of Stroke.

The research has potentially important financial as well as medical implications, Uswatte said. "Today it is difficult for stroke patients to get reimbursement for treatment six to 12 months after a stroke," he said, noting that the new study might help change that.

The trial included 41 middle-aged people who had mild to moderate loss of function in one arm because of a stroke that occurred, on average, 4.5 years after the study began. Twenty of patients went through a general fitness program that included strength, balance and stamina training and relaxation exercises six hours a day for 10 consecutive weekdays.

The other 21 had their healthy arm constrained by a hand splint or sling about 90 percent of the time for two weeks and also had intensive training of the affected arm.

The people who got what is formally called constraint-induced movement therapy reported significant improvement in function of the affected arm. "They scored, on average, 1 on a scale of 1 to 4 before treatment and 3 after," Uswatte said. No significant change occurred in the other patient group.

And while the study focused only on arms, "we have done other studies showing that patients with mild to severe deficit of other limbs can benefit from the treatment," he said.

Constraint-induced movement therapy is offered by a number of institutions, but is not widely available "because of the barrier of insurance coverage," Uswatte said. "Clinics offer the treatment on a fee-for-service basis, so patients have to pay out of their own pocket."

Dr. Elizabeth Noser, an assistant professor of neurology at the University of Texas Medical School at Houston, agreed that such treatments can prove costly to patients. "You're talking about six hours of therapy a day for 10 to 12 days," she said. "That's expensive."

A clinic that will offer constraint therapy along with other treatments is being opened by the Houston medical center, in collaboration with HealthSouth Corp., she said.

The effectiveness of the therapy has been demonstrated on brain images, Noser said. "More brain cells are activated after constraint therapy," she said. Still, "health insurance companies say that not enough definitive trials have been done, so patients have to pay out of pocket," she added.

There's hope the results of a multi-center trial now under way, expected to be published in the next few months, will help change that stance, Uswatte said.

The Alabama study makes two major points, he said: "There is now hope for patients long after a stroke, and also an emphasis on transferring gains made in the laboratory into a clinical setting."

More information

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Chinese Cover of The Neuro Revolution
The Neuro Revolution Lands In China
How Neuroscience Will Change the World - My Interview on Reason.tv
Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm
The Neuro Revolution Published in Japan as "Neuro Wars"
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20